Targeting a specific receptor to improve treatment for inflammatory neuropathies
Modulation of CSF1R Signaling to Treat Inflammatory Neuropathies
['FUNDING_R01'] · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · NIH-10997374
This study is looking at how a specific treatment might help people with Guillain-Barré syndrome by blocking a receptor that contributes to nerve damage, with the hope of finding better options for those who are struggling with this condition.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON (nih funded) |
| Locations | 1 site (HOUSTON, UNITED STATES) |
| Trial ID | NIH-10997374 on ClinicalTrials.gov |
What this research studies
This research investigates the role of the colony stimulating factor 1 receptor (CSF1R) in the treatment of Guillain-Barré syndrome (GBS), a condition that can cause acute flaccid paralysis. The study aims to explore how blocking this receptor can reduce nerve injury caused by inflammatory cells during the acute phase of GBS. By focusing on the mechanisms that lead to nerve damage, the research seeks to develop more effective immunomodulatory treatments that could benefit patients who currently have limited options. The approach includes both human studies and animal models to validate the findings.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Guillain-Barré syndrome, particularly those who have not responded well to existing treatments.
Not a fit: Patients with chronic neuropathies or those whose conditions are not related to inflammatory processes may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatments for patients suffering from inflammatory neuropathies, potentially reducing long-term disability.
How similar studies have performed: Previous research has shown promise in targeting similar inflammatory pathways, suggesting that this approach could yield significant advancements in treatment.
Where this research is happening
HOUSTON, UNITED STATES
- UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON — HOUSTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: SHEIKH, KAZIM A — UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON
- Study coordinator: SHEIKH, KAZIM A
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Acute Disease, acute disease/disorder, acute disorder